Envision Pharma Group acquires Two Labs

Envision Pharma Group recently announced the acquisition of Two Labs, a leading biotechnology and pharmaceutical industry supplier of tailored and integrated commercial solutions.

The acquisition will bring together complementary services, customers and innovations that will broaden the scientific reach of Envision to
new customers while unlocking new market geographies and avenues for the industry-leading launch planning services of Two Lab.

CEO of Envision, David Thompson, stated: “This exciting combination of Envision and Two Labs creates a compelling and unrivalled proposition in launch excellence partnership globally and in the US. We look forward to sharing our joint expertise and leveraging our complementary services across medical affairs, and product launch planning to support our clients in their goal of bringing new medicines to market effectively and compliantly, to improve patient outcomes.”

CEO of Two Labs, Howard Miller, stated: “We are delighted to be joining the Envision family and taking Two Labs to the next logical step in its successful journey to date. With Envision’s global footprint and Two Labs’ market-leading US footprint – we have a unique opportunity to enrich our client partnerships with more connected services across the launch continuum. The cultural fit between our organizations is compelling and we look forward to a new chapter for Two Labs in partnering with David and the Envision team.”

The Partners at GHO stated: “We are glad to welcome Howard and the Two Labs team to the Envision Group. They have built a market-leading strategic consulting and commercialisation business that in combination with Envision’s position as the go-to tech-enabled scientific communications company will deliver major value to global pharma and biotech through a combined, unique launch excellence offering that accelerates and improves their route to market.”